The increasing incidences of atrial fibrillation, strokes due to
blood clots and brain damages are the major factors driving the global
atrial fibrillation market. Furthermore, the rising geriatric population
base globally suffering from various heart diseases is also a factor
propelling the atrial fibrillation market. Some of the other drivers for
the global atrial fibrillation market include the rising prevalence of
diseases caused by lifestyle habits such as excessive alcohol
consumption and smoking.
As atrial fibrillation patients have risk of blood clot formation and
occurrence of strokes, patients are also treated with anti-clotting and
blood thinning medications. The increased demand for atrial
fibrillation and minimally invasive procedures is a direct consequence
of rapidly increasing incidences of heart failures, congenital heart
diseases and coronary artery diseases all over the world. In young
patients, sometimes heart rhythm control cannot be maintained through
medication or cardioversion, then radiofrequency ablation can be
attempted to control the heart rhythm.
Browse Detail Report With TOC @ http://www.hexaresearch.com/research-report/atrial-fibrillation-industry/
The technological advancements in the field of radiofrequency
ablation such as the introduction of remotely obtained computed
tomography has also increased the growth of the atrial fibrillation
market. The risk of atrial fibrillation disease increases with age. As
stated by WHO, 8% of people who are over the age of 80 suffer from some
kind of atrial fibrillation. The increasing incidences of atrial
fibrillation triggering diseases globally, such as obesity, pneumonia,
pulmonary embolus, high blood pressure, hyperthyroidism and mitral
stenosis is the factor expected to further fuel the atrial fibrillation
market over the forecast period.
The global atrial fibrillation market is segmented on the basis of
pharmacological procedures and non pharmacological procedures. The
pharmacological treatments involve anti coagulant drugs and anti
arrhythmic drugs. The non pharmacological procedures are the therapies
which does not include drugs for the diagnosis of diseases. The non
pharmacological procedure includes diagnosis through procedures such as
electric cardioversion, maze surgery and catheter ablation.
The surgical catheter ablation dominates the atrial fibrillation
market owing to an extremely high success rate in most arrhythmias. The
surgical catheter ablation includes several procedures. The most
commonly used procedure in catheter ablation includes microwave catheter
ablation and radiofrequency catheter ablation. Their increased
application is a consequence of faster recovery and the reduced size of
cardiac incision.
The global atrial fibrillation market is segmented on the basis of
key regions into North America, Asia Pacific, Europe and RoW. As of
2013, North America dominated the atrial fibrillation market owing to
the huge patient base suffering from heart diseases and the presence of
highly elevated procedure volumes which are supported by the presence of
refined healthcare infrastructure in this region. Asia Pacific is
expected to show lucrative growth over the forecast period owing to the
high patient awareness and rapidly increasing healthcare expenditure
levels in this region.
Request A Sample copy of This Report @ http://www.hexaresearch.com/sample/5
The key players in the global atrial fibrillation market include
Boehringer Ingelheim GmbH, Johnson & Johnson Ltd., St. Jude Medical
Inc., Endoscopic Technologies Inc., Bristol Myers Squibb Corporation,
Boston Scientific Corporation, Cardiofocus Inc., AtriCure Inc., Biosense
Webster Inc. and Sanofi Aventis. The market leaders in the global
atrial fibrillation market are involved in constant attempts for the
development of innovative methodologies which would increase the
efficiency and accuracy of atrial fibrillation diagnosis while providing
the efficient processing of the overall treatment.
This companies are also entering into strategic collaborations,
expansions and new product launches to extend their global patient base.
St. Jude Medical Inc. has introduced an innovative Endosense’s Tacti
Cath which is efficient to provide live feedback regarding applied
pressure during microwave catheter ablations and radiofrequency catheter
ablations. Owing to rise in the implementation of these procedures, it
is expected that TactiCath will also witness a huge growth in demand.
Browse Full Report @ http://www.hexaresearch.com/research-report/atrial-fibrillation-industry/
About Us:
Hexa Research is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
No comments:
Post a Comment